[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100512511":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":18,"centralContacts":21,"locations":29,"responsibleParty":47,"collaborators":10,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":10,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":10,"maxAge":10,"enrollmentInfo":57,"targetDuration":60,"studyType":61,"phases":10,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Bristol-Myers Squibb","INDUSTRY",[8,12,15],{"label":9,"type":10,"description":11,"interventionNames":10},"Ozanimod-exposed participants with UC",null,"Pregnant women with a diagnosis of UC who are exposed to ozanimod at any time during pregnancy",{"label":13,"type":10,"description":14,"interventionNames":10},"Conventional therapy-exposed participants with UC","Pregnant women with a diagnosis of UC who are exposed to conventional therapies (aminosalicylates and\u002For thiopurines) but not exposed to ozanimod, other S1P therapies, or advanced therapies for UC (biologics and\u002For small molecules) at any time during pregnancy",{"label":16,"type":10,"description":17,"interventionNames":10},"Advanced therapy-exposed participants with UC","Pregnant women with a diagnosis of UC who are exposed to advanced therapies for UC (biologics and\u002For small molecules) but not exposed to ozanimod or other S1P therapies at any time during pregnancy",[19],{"name":5,"affiliation":5,"role":20},"STUDY_DIRECTOR",[22,27],{"name":23,"role":24,"phone":25,"phoneExt":10,"email":26},"BMS Study Connect Contact Center www.BMSStudyConnect.com","CONTACT","855-907-3286","Clinical.Trials@bms.com",{"name":28,"role":24,"phone":10,"phoneExt":10,"email":10},"First line of the email MUST contain the NCT# and Site #.",[30],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"PPD Virtual - PPD - US","RECRUITING","Wilmington","North Carolina","28401-3331","United States","US",{"type":39,"coordinates":40},"Point",[41,42],-77.94604,34.23556,{"lat":42,"lon":41},[45],{"name":46,"role":24,"phone":10,"phoneExt":10,"email":10},"Site 0001",{"type":48,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100512511","a-study-of-ozanimod-in-pregnant-women-with-ulcerative-colitis-and-their-offspring-100512511",false,"NCT05953402","A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their Offspring","ZEPOSIA® (Ozanimod) Ulcerative Colitis Pregnancy Registry: a Prospective, Observational Study on the Safety of Ozanimod Exposure in Pregnant Women With Ulcerative Colitis and Their Offspring","Inclusion Criteria:\n\n* Currently or recently pregnant\n* Diagnosis of UC\n* Resident of country where ozanimod is prescribed for the treatment of UC\n\nExclusion Criteria:\n\n* Exposure to other S1P therapies at any time during pregnancy\n\nOther protocol-defined eligibility criteria apply.","FEMALE",{"count":58,"type":59},1182,"ESTIMATED","21 Months","OBSERVATIONAL","The purpose of this study is to evaluate association between ozanimod exposure during pregnancy and subsequent maternal, fetal, and infant outcomes.",[64],"Ulcerative Colitis",[66,67,68,69,70,71,64,72],"ZEPOSIA®","Ozanimod","Pregnancy","Sphingosine-1-phosphate (S1P) therapies","Inflammatory Bowel Disease","IBD","UC","2026-06-12",{"date":75,"type":76},"2026-06-15","ACTUAL",{"date":78,"type":76},"2026-04-21",{"date":80,"type":59},"2034-06-30",{"name":5,"class":6},1]